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Azole Antifungal Sensitivity of 
Sterol 14α-Demethylase (CYP51) 
and CYP5218 from Malassezia 
globosa
Andrew G. S. Warrilow1, Claire L. Price1, Josie E. Parker1, Nicola J. Rolley1, 
Christopher J. Smyrniotis2, David D. Hughes3, Vera Thoss3, W. David Nes4,  
Diane E. Kelly1, Theodore R. Holman2 & Steven L. Kelly1
Malassezia globosa cytochromes P450 CYP51 and CYP5218 are sterol 14α-demethylase (the target 
of azole antifungals) and a putative fatty acid metabolism protein (and a potential azole drug target), 
respectively. Lanosterol, eburicol and obtusifoliol bound to CYP51 with Kd values of 32, 23 and 28 μM, 
respectively, catalyzing sterol 14α-demethylation with respective turnover numbers of 1.7 min−1, 
5.6 min−1 and 3.4 min−1. CYP5218 bound a range of fatty acids with linoleic acid binding strongest 
(Kd 36 μM), although no metabolism could be detected in reconstitution assays or role in growth on 
lipids. Clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole and ketaminazole bound 
tightly to CYP51 (Kd ≤ 2 to 11 nM). In contrast, fluconazole did not bind to CYP5218, voriconazole 
and ketaminazole bound weakly (Kd ~107 and ~12 μM), whereas ketoconazole, clotrimazole and 
itraconazole bound strongest to CYP5218 (Kd ~1.6, 0.5 and 0.4 μM) indicating CYP5218 to be only a 
secondary target of azole antifungals. IC50 determinations confirmed M. globosa CYP51 was strongly 
inhibited by azole antifungals (0.15 to 0.35 μM). MIC100 studies showed itraconazole should be 
considered as an alternative to ketoconazole given the potency and safety profiles and the CYP51 assay 
system can be used in structure-activity studies in drug development.
Malassezia species are known to play a role in several human skin diseases including dandruff, seborrheic der-
matitis, pityriasis versicolor and malassezia folliculitis and may also exacerbate atopic dermatitis and psoriasis1–5 
even though they are members of the normal skin microbial flora, being present on the skin of 75 to 98% of 
healthy individuals6. There are presently fourteen recognized species of Malassezia, eight of which are associ-
ated with humans7. Malassezia are unique amongst fungi in requiring exogenous lipids for growth. Malassezia 
species have evolved through an expansion of lipid hydroxylases (14 lipases in M. globosa) and a reduction in 
carbohydrate metabolism genes which may have contributed to the evolution of the genus from plant to ani-
mal inhabitants8. The predominant species found in dandruff and seborrheic dermatitis sufferers are elevated 
levels of M. globosa and M. restricta9,10 preferring sebum-rich areas of skin, degrading the sebum by secreting 
lipases11. Dandruff may affect 50% of individuals and the more severe seborrheic dermatitis affects 1 to 3% of the 
population3,4.
The most commonly used antifungal agents to treat topical M. globosa infections are ketoconazole12,13 target-
ing sterol 14α -demethylase (CYP51), hydroxypiridones3,14–17, especially ciclopiroxolamine17 which targets a vari-
ety of metabolic processes including depletion of trivalent metal cations18 and zinc pyrithione19,20 which causes 
elevated copper levels in yeast cells21. Alternate drug targets in M. globosa being evaluated include β -carbonic 
anhydrase inhibition by sulfonamide, sulfamates and sulfamide drugs22.
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Azole antifungal agents selectively target fungal CYP51 enzymes over the human homolog23 through the 
direct coordination of the triazole ring N-4 nitrogen (fluconazole, itraconazole and voriconazole) or the ima-
dazole ring N-3 nitrogen (clotrimazole and ketoconazole) with the heme iron as the sixth axial ligand24. Azole 
antifungals can also coordinate with the heme iron of other cytochrome P450 enzymes, raising the possibility of 
alternative and secondary drug targets. CYP52 proteins are known to be involved in growth on alkanes and fatty 
acids in yeasts and a homolog has been described in Malassezia25 that might represent a drug target to inhibit 
growth on these carbon sources.
Many systemic and superficial fungal infections are also associated with tissue inflammation involving human 
5-lipoxygenase (5-LOX), such as dandruff 26. Therefore a therapeutic agent that possessed both antifungal and 
anti-inflammatory activity would be advantageous. The drug candidate ketaminazole27, possessing antifungal 
activity through an imidazole moiety and anti-inflammatory action through a phenylenediamine moiety, was 
shown to be a potent inhibitor of Candida albicans CYP51 and human 5-LOX. In this study, the expression, 
purification and characterization of two M. globosa cytochrome P450 monooxygenase proteins (CYP51 and 
CYP5218) are described and the effectiveness of azole antifungal agents against M. globosa CYP51 and CYP512 
including inhibition of M. globosa growth are determined.
Results
Purification of CYP51 and CYP5218 proteins. Cholate extraction yielded ~320 (± 100) and ~120 (± 30) 
nmoles per liter culture of CYP51 and CYP5218. Purification by Ni2+-NTA agarose chromatography resulted 
in 61% and 66% recoveries of native M. globosa CYP51 and CYP5218 proteins. SDS polyacrylamide gel electro-
phoresis confirmed the purity to be greater than 90% when assessed by staining intensity. The apparent molec-
ular weights of M. globosa CYP51 and CYP5218 proteins were 53000 (± 3000) and 58000 (± 4000), which were 
slightly lower than the predicted values of 59786 and 69833, including N-terminal modifications and 4-Histidine 
C-terminal extensions. The absolute spectra of the resting oxidized form of M. globosa CYP51 and CYP5218 
(Fig. 1A) were typical for low-spin ferric cytochrome P450 enzymes predominantly in the low-spin state28,29 
with α , β , Soret (γ ) and δ spectral bands at 571, 538, 418 and 360 nm for CYP51 and 565, 529, 415, 363 nm for 
CYP5218. Reduced carbon monoxide difference spectra for CYP51 and CYP5218 (Fig. 1B,C) gave the red-shifted 
heme Soret peak at 447 nm characteristic of P450 enzymes, indicating both proteins were expressed in the native 
form.
Figure 1. Spectral characteristics of M. globosa CYP51 and CYP5218. Absolute spectra (A) were determined 
using 3 μ M purified M. globosa CYP51 (solid line) and CYP5218 (dashed line) in the oxidised resting state (light 
path 4.5 mm). Reduced carbon monoxide difference spectra were determined using 3 μ M purified M. globosa 
CYP51 (B) and CYP5218 (C) with sequential measurements made every 45 seconds (light path 10 mm).
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Substrate binding properties. Progressive titration of M. globosa CYP51 with eburicol gave a type I dif-
ference spectrum with a peak at 388 nm and a trough at 421 nm (Fig. 2A). Similar spectra were obtained using 
lanosterol and obtusifoliol. Type I binding spectra occur when the substrate or another molecule displaces the 
water molecule coordinated as the sixth ligand to the low-spin hexa-coordinated heme prosthetic group causing 
the heme to adopt the high-spin penta-coordinated conformation29. Binding affinities for the three sterols were 
similar with Kd values of 32, 23 and 28 μ M for lanosterol, eburicol and obtusifoliol, respectively.
Progressive titration of CYP5218 with palmitoleic acid gave a type I difference spectrum (Fig. 2B). The binding 
spectra obtained with the other fatty acids are shown in supplementary Figure S1. The binding affinities for most 
fatty acids with CYP5218 were similar (Kd = 90 to 250 μ M) except for linoleic acid (Kd = 36 μ M), which bound 
2.5- to 7-fold more tightly to CYP5218 (Table 1) and with similar affinity to sterols binding to M. globosa CYP51. 
No binding spectra were obtained for CYP5218 with capric acid (C10:0), arachidic acid (C20:0), n-hexadecane 
and 1-hexadecene, indicating saturated fatty acids shorter than C12 and larger than C18 in addition to alkanes 
and alkenes did not bind to CYP5218 by perturbing the heme environment. Lanosterol and eburicol both failed 
to give reproducible binding spectra with CYP5218 (data not shown), excluding sterols as potential substrates.
CYP reconstitution assays. GC/MS analysis was used to identify CYP51 and CYP5218 assay metabolites. 
CYP51 assays using 0.5 μ M M. globossa CYP51 and 50 μ M obtusifoliol gave a turnover number of 3.4 min−1 com-
pared with 1.7 min−1 for lanosterol and 5.6 min−1 for eburicol indicating M. globosa CYP51 had been isolated in 
a fully functional form exhibiting a preference for eburicol and obtusifoliol as substrate over lanosterol. Product 
identities were confirmed by the mass fragmentation patterns (Figures S2–S4) to be 14-demethylated sterols. 
Enzyme velocity curves for 0.13 μ M M. globossa CYP51 (Figure S5) indicated substrate inhibition at higher sterol 
concentrations, especially for obtusifoliol and eburicol. Calculated Kcat values of 22.47 ± 2.19, 65.54 ± 16.05 and 
53.69 ± 14.21 min−1 for lanosterol, eburicol and obtusifoliol confirm an apparent catalytic preference for eburicol 
and obtusifoliol over lanosterol, however, Km values were similar for all three sterols at 55.14 ± 6.51, 55.91 ± 19.79 
and 42.09 ± 10.45 μ M, respectively.
Reconstitution assays with CYP5218 resulted in no observed product formation using lauric acid, myristic 
acid, palmitic acid, palmitoleic acid, oleic acid and linoleic acid as substrates. This was despite increasing the 
duration of the assay from 1 hour to overnight (~16 h) and using three different cytochrome P450 reductase redox 
partners. Therefore fatty acids of chain length C12 to C18 were not CYP5218 substrates.
Figure 2. Type I substrate binding spectra. Absorbance difference spectra obtained by the progressive 
titration of 5 μ M CYP51 with eburicol (A) and 4 μ M CYP5218 with palmitoleic acid (B) were measured. 
Saturation curves (C) for eburicol (filled circles) and palmitoleic acid (hollow circles) were constructed from the 
absorbance difference spectra. Ligand binding data were fitted using the Michaelis-Menten equation with each 
experiment performed in triplicate although only one replicate is shown.
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Azole binding properties and IC50 determinations. Titration of M. globosa CYP51 and CYP5218 with 
itraconazole produced type II binding spectra (Fig. 3A,B) with a peak at ~429 nm and a trough at ~412 nm. 




Capric acid no binding no binding
Lauric acid 136 ± 4 136 ± 3
Myristic acid 195 ± 41 245 ± 29
Palmitic acid 1020 ± 755a 253 ± 77a
Stearic acid no fita no fita
Arachidic acid no binding no binding
Lauroleic acid poor fit 148 ± 20
Myristoleic acid 158 ± 20 151 ± 8
Palmitoleic acid 113 ± 7 114 ± 5
Oleic acid 93 ± 11 90 ± 16
Linoelic acid 36 ± 4 36 ± 6
Arachidonic acid 264 ± 34 256 ± 36
Table 1.  Fatty acid binding affinities for M. globosa CYP5218. M. globosa CYP5218 (4 μ M) was progressively 
titrated with fatty acids. Saturation curves were constructed from the absorbance difference Δ Apeak-trough of 
the type I binding spectra obtained. The Michaelis-Menten equation was used to fit the ligand binding data 
in addition to Eadie-Hofstee analysis. Mean Kd values from three replicates are shown along with standard 
deviations. aprecipitation of fatty acid was apparent.
Figure 3. Type II itraconazole binding spectra. Itraconazole was progressively titrated against 2 μ M CYP51 
(A) and 2 μ M CYP5218 (B) with the difference spectra determined after each addition of triazole. Itraconazole 
saturation curves (C) were constructed from the type II absorbance difference spectra for CYP51 (filled circles) 
and CYP5218 (hollow circles). The data were fitted using a rearrangement of the Morrison equation47. Each 
experiment was performed in triplicate although only one replicate is shown.
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ketaminazole are shown in supplementary Figure S6. Type II binding spectra are caused by the triazole ring N-4 
nitrogen (fluconazole, itraconazole and voriconazole) or the imidazole ring N-3 nitrogen (clotrimazole, ketocona-
zole and ketaminazole) coordinating as the sixth ligand with the heme iron24 to form the low-spin CYP51-azole 
complex resulting in a ‘red-shift’ of the heme Soret peak. All six azole antifungals bound to M. globosa CYP51 
(Figure S6), however, fluconazole did not bind to M. globosa CYP5218 whereas clotrimazole, voriconazole, itra-
conazole, ketoconazole and ketaminazole all gave type II binding spectra with CYP5218.
Binding saturation curves (Fig. 3C and supplementary Figure S7) confirmed that azole binding to CYP51 was 
very tight with Kd values of 4 ± 2, 11 ± 4, 2 ± 1, 2 ± 1, 8 ± 5 and 3 ± 1 nM for clotrimazole, fluconazole, itracona-
zole, ketoconazole, voriconazole and ketaminazole, respectively. Azole binding to CYP5218 was weaker with 
itraconazole and clotrimazole binding the tightest (Kd 407 ± 136 and 486 ± 28 nM). Binding affinity to CYP5218 
progressively fell from ketoconazole, ketaminazole and voriconazole (Kd values ~1.6 ± 0.2, ~11.7 ± 0.5 and 
~107 ± 2.2 μ M) suggesting that these azoles would be ineffective at inhibiting CYP5218 activity.
IC50 determinations (Fig. 4) confirmed that M. globosa CYP51 bound fluconazole, itraconazole, ketoconazole 
and ketaminazole tightly with IC50 values approximately half the CYP51 concentration present at 0.206 ± 0.008, 
0.188 ± 0.008, 0.176 ± 0.016 and 0.321 ± 0.042 μ M, respectively. Similarly tight binding azole IC50 values were 
observed for C. albicans CYP5123. The ketaminazole IC50 value was less than two-fold higher than the current 
therapeutic azole drugs and was 45-fold lower than the IC50 value determined for ketaminazole with human 
CYP5127, suggesting ketaminazole could be an effective antifungal agent against M. globosa with minimal inhi-
bition of human CYP51.
M. globosa MIC determinations. Both itraconazole and ketoconazole strongly inhibited M. globosa 
growth with MIC100 values of 0.0625 and 0.25 μ g ml−1. Voriconazole was moderately effective with a MIC100 
value of 1 μ g ml−1 whereas clotrimazole, ketaminazole and fluconazole were poor inhibitors of M. globosa growth 
(MIC100 values of 8, 8, and 64 μ g ml−1). The high MIC100 value for fluconazole (64 μ g ml−1) compared to the low 
IC50 for fluconazole with M. globosa CYP51 (0.2 μ M) suggests rapid efflux of this azole from cells. Ketaminazole 
was 32-fold less effective than ketoconazole at arresting M. globosa growth and 128-fold less effective than itra-
conazole, however, partial inhibition of growth was observed with 4 μ g ml−1 ketaminazole. Therefore ketamina-
zole appears substantially less effective at inhibiting M. globosa growth than itraconazole and ketoconazole given 
the two-fold difference in the CYP51 IC50 values. The treatment of M. globosa with 0.125 μ g ml−1 ketoconazole 
and 4 μ g ml−1 ketaminazole resulted in the accumulation of eburicol (Table 2). Accumulation of CYP51 substrates 
is indicative of direct in vivo CYP51 inhibition along with a reduction in the abundance of other post-CYP51 
sterol metabolites.
Discussion
Phylogenetic analysis of MGL_2415 strongly suggested this gene encoded a CYP51 enzyme. All 23 conserved 
CYP51 residues30 were present in the amino acid sequence and the top 100 BLASTP matches were predominantly 
CYP51 enzymes. In contrast, a similar analysis for MGL_3996 (CYP5218) failed to identify a putative catalytic 
function for this cytochrome P450 enzyme. Previously Lee et al.25 had reported that MGL_3996 was probably 
a CYP52 enzyme. BLAST2 analyses of CYP5218 against other yeast CYP52s showed less than 40% sequence 
identity. Such low sequence identities between CYP52 proteins and MGL_3996 suggest CYP5218 is not a CYP52 
enzyme.
Figure 4. IC50 determinations for azole antifungal agents. CYP51 reconstitution assays were performed 
using a CYP51:AfCPR1 ratio of 1:2 for 0.5 μ M M. globosa CYP51 with 50 μ M lanosterol as substrate at varying 
fluconazole (filled circles) itraconazole (hollow circles), ketoconazole (bullets) and ketaminazole (crosses) 
concentrations from 0 to 4 μ M. Mean relative velocity values are shown along with standard deviation bars. 
Relative velocities of 1.00 were equivalent to velocities of 1.79 ± 0.26 min−1.
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The spectral properties of purified M. globosa CYP51 and CYP5218 suggest both proteins were expressed in 
their native low-spin states. This was further supported by CYP51 binding 14-methylated sterols and CYP5218 
binding fatty acids (Fig. 2). The M. globosa CYP51 Kd values for lanosterol and eburicol were similar to those 
obtained with Candida albicans CYP5131, Mycosphaerella graminicola CYP5132, and Aspergillus fumigatus 
CYP51B33, but were 20-fold larger than Kd values obtained with Trypanosoma cruzei CYP5134. Eburicol, lanos-
terol and obtusifoliol were demethylated by M. globosa CYP51 confirming the enzyme was isolated in native form. 
The catalytic rates observed with M. globosa CYP51 were similar to those of other CYP51 enzymes35. Previously 
M. globosa CYP51 was expressed and purified by Kim et al.36, but they did not demonstrate catalytic turnover.
Type I fatty acid binding spectra with M. globosa CYP5218 suggested that this enzyme metabolized fatty acids 
(hydroxylation or desaturation) with linoleic acid (C18:2) being favored because of the significantly lower Kd 
value (36 μ M) and therefore might be implicated in the use of fatty acids as carbon source for growth.
The fatty acid binding Kd values observed for CYP5218 were similar to those determined for Candida maltosa 
CYP52A4 with lauric and myristic acids (~110 and ~120 μ M)37. Lee et al.25 had previously expressed CYP5218 in 
Pichia pastoris at low levels, but did not purify or characterize the enzyme in terms of substrate binding properties 
or catalytic activity. Despite CYP5218 binding fatty acids, no in vitro metabolism of lauric acid, myristic acid, pal-
mitic acid, palmitoleic acid, oleic acid or linoleic acid could be detected using the CYP5218 reconstitution assay 
with AfCPR1, CaCPR or HsCPR as redox partners. This suggests that fatty acids are not the in vivo substrates of 
CYP5218 in M. globosa. This phenomenon has previous been observed with cytochrome P450 BM3 mutants38. 
The fatty acids entered the enlarged substrate binding channel/pocket displacing the axial hexa-coordinated heme 
water molecule causing a low- to high-spin state change but did not undergo metabolism as the fatty acid mole-
cule remained too distant from the heme iron for catalysis to occur.
Azole ligand binding studies indicated that M. globosa CYP51 bound azole antifungal agents 120- to 
13300-fold more tightly than CYP5218 based on Kd values. Therefore azole antifungals would need to be rede-
signed if CYP5218 was to be the primary drug target. At present only itraconazole and clotrimazole appear to 
have reasonably high affinities for CYP5218, albeit with 200- and 120-fold higher Kd values than for CYP51. The 
drug candidate ketaminazole bound tightly to M. globosa CYP51 (Kd 3 nM) suggesting ketaminazole would be 
effective at inhibiting CYP51 activity and M. globosa growth. In comparison, C. albicans CYP51 had Kd values 
for pharmaceutical azoles of 10 to 56 nM23 and a Kd value of 43 nM with ketaminazole27. In contrast, H. sapiens 
CYP5123,39 had higher Kd values of 42 nM to 70 μ M for pharmaceutical azoles and a Kd value of 731 nM for ketam-
inazole27. Therefore ketaminazole exhibited a 240-fold selectivity for M. globosa CYP51 over the human homolog 
based on Kd values compared to a 17-fold selectivity for C. albicans CYP5127.
IC50 determinations (Fig. 4) confirmed that M. globosa CYP51 was strongly inhibited by azole antifungal 
agents (IC50 values of 0.15 to 0.35 μ M), suggesting efficacy against M. globosa cultures. However, the effectiveness 
of azole antifungals at inhibiting M. globosa cell growth was variable with itraconazole and ketoconazole being 
effective (MIC100 values 0.0625 and 0.25 μ g ml−1) and voriconazole being moderately effective (MIC100 1 μ g ml−1), 
whereas clotrimazole, ketaminazole and fluconazole were poor inhibitors of M. globosa growth (MIC100 values 8, 
8 and 64 μ g ml−1). The mode of action for the azole antifungals against M. globosa was confirmed by sterol anal-
ysis of 0.125 μ g ml−1 ketoconazole- and 4 μ g ml−1 ketaminazole-treated cell pellets which showed raised eburicol 
levels compared to untreated cells (Table 2). Accumulation of 14-methylated sterols, such as eburicol, is charac-
teristic of in vivo CYP51 inhibition by azole antifungal agents. The increased susceptibility of ketaminazole to 
both hydrolysis and oxidative stress in comparison to ketoconazole may partially explain the higher MIC100 values 
observed with ketaminazole when using broth-cultured M. globosa. The drug transporter inhibitor FK-506 was 
found to be cytotoxic towards M. globosa at concentrations above 0.0625 μ g ml−1 preventing the assessment of the 
contribution of drug transporters towards azole resistance observed with ketaminazole relative to ketoconazole. 
Further investigations into the reduced potency of ketaminazole, especially in comparison to itraconazole and 
ketconazole, are required to establish whether altering the structure of the compound can overcome these appar-
ent shortcomings. The MIC100 values determined in this study were towards the upper end of the MIC values 
Sterols
Azole-treated M. globosa sterol fraction (%)
Untreated 0.125 μg ml−1 Ketoconazole 4 μg ml−1 Ketaminazole
Cholesterola 1.31 1.92 1.21
Ergosterol 50.33 51.50 54.64
Ergosta-8,22-dienol 9.06 1.89 5.35
Fecosterol 0.31 0.98 0.54
Ergosta-8-enol 3.23 2.23 0
Ergosta-5,7-dienol 17.40 9.39 13.85
Episterol 0.91 0 0.63
Ergosta-7-enol 8.65 1.58 5.00
Obtusifoliol 2.22 0.18 3.52
4,4-dimethylzymosterol 2.37 0 0.62
Eburicol 4.20 30.33 14.63
Table 2.  Sterol composition of azole-treated M. globosa. acholesterol assimilated from growth media 
containing ox-bile.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:27690 | DOI: 10.1038/srep27690
previously reported of 0.016 to 0.25 μ g ml−1 for itraconazole, 0.03 to 0.06 μ g ml−1 for voriconazole, 0.008 to 0.25 μ g 
ml−1 for ketoconazole, 0.06 μ g ml−1 for posaconazole and 4 μ g ml−1 for fluconazole40–43.
In summary, M. globosa CYP5218 was observed to bind fatty acids but was not associated with metabolism 
and its function and potential as a drug target remains unclear. In contrast the known drug target CYP51 readily 
catalyzed the 14α -demethylation of lanosterol, eburicol and obtusifoliol and bound all six pharmaceutical azoles 
tightly (Kd 2 to 11 nM) reflected in the low IC50 values for azole antifungals. The performance of the drug candi-
date ketaminazole against M. globosa CYP51 was encouraging with a Kd value similar to the other pharmaceutical 
azoles and an IC50 value only twice that of ketoconazole. However, MIC100 studies showed ketaminazole to be 
~32-fold less effective at inhibiting M. globosa growth than ketoconazole, suggesting that the chemical structure 
of ketaminazole needs further optimization for increased cellular uptake and antifungal potency in vivo. A CYP51 
assay was demonstrated that can be used for drug discovery and a case demonstrated for using itraconazole given 
the superior safety profile over ketoconazole.
Materials and Methods
Heterologous expression and purification of recombinant proteins. The M. globosa CYP51 gene 
(Mglob51 - KEGG M. globosa genome database http://www.genome.jp/dbget-bin/www_bget?mgl:MGL_2415) 
and CYP5218 gene (Mglob5218 - http://www.genome.jp/dbget-bin/www_bget?mgl:MGL_3996) were synthe-
sized by Eurofins MWG Operon (Ebersberg, Germany) and cloned into the pCWori+ expression vector. The 
first eight amino acids of each protein were changed to ‘MALLLAVF’44 and a four-histidine tag added to the 
C’ terminus. The pCWori+:Mglob51 and pCWori+:Mglob5218 constructs were transformed into DH5α E. coli 
cells. M. globosa CYP51 was expressed as previously described31 whilst for CYP5218 the expression temperature 
was lowered to 20 °C for 18 h at 180 rpm. Recombinant proteins were isolated according to the method of Arase 
et al.45 and solubilized CYP51 and CYP5218 proteins were purified using Ni2+-NTA agarose28. Protein purity was 
assessed by SDS polyacrylamide gel electrophoresis.
Cytochrome P450 spectroscopy. Reduced carbon monoxide difference spectroscopy46,47 and abso-
lute spectra between 700 and 300 nm were used to determine cytochrome P450 concentrations. Substrate 
and azole binding studies were performed31,48 using 2.5 mM stock sterol solutions in 40% (wt/vol) 
(2-hydroxypropyl)-β -cyclodextrin (HPCD), 4 mg ml−1 solutions of fatty acids in dimethylformamide (DMF), 
and stock 0.05, 0.1 and 0.2 mg ml−1 solutions of azole antifungal agents in dimethylsulfoxide (DMSO). Sterols 
were titrated against 5 μ M CYP51, fatty acids were titrated against 4 μ M CYP5218 and azole antifungal agents 
were titrated against 2 μ M CYP51 and CYP5218. The absorbance difference spectrum between 500 and 350 nm 
was determined after each incremental addition of ligand with saturation curves constructed from Δ Apeak-trough 
against ligand concentration. The dissociation constants (Kd) for sterols and fatty acids were determined by 
non-linear regression (Levenberg-Marquardt algorithm) using the Michaelis-Menten equation. The dissociation 
constants of the enzyme-azole complex were determined by non-linear regression (Levenberg-Marquardt algo-
rithm) using a rearrangement of the Morrison equation for tight ligand binding49,50. ProFit 6.1.12 (QuantumSoft, 
Zurich, Switzerland) was used for curve-fitting data. All ligand-binding studies were performed at 22 ± 2 °C and 
in triplicate. All spectral determinations were made using a Hitachi U-3310 UV/VIS spectrophotometer (San 
Jose, California).
CYP reconstitution assays. CYP51 reconstitution assays34,51 contained 0.5 μ M M. globosa CYP51, 1 μ M 
Aspergillus fumigatus cytochrome P450 reductase isoenzyme 1 (AfCPR1 - UniProtKB accession number 
Q4WM6752), 50 μ M 14α -methylated sterol (lanosterol, eburicol or obtusifoliol), 50 μ M dilaurylphosphatidyl-
choline, 4% (wt/vol) HPCD, 0.4 mg ml−1 isocitrate dehydrogenase, 25 mM trisodium isocitrate, 50 mM NaCl, 
5 mM MgCl2 and 40 mM MOPS (pH ~7.2). Assay mixtures were incubated at 37 °C for 10 minutes prior to ini-
tiation with 4 mM β -NADPHNa4 followed by shaking at 37 °C for 20 minutes. Sterol metabolites were recovered 
by extraction with ethyl acetate followed by derivatization with 0.1 ml N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) : trimethylchlorosilane (TMCS) (99:1) and 0.3 ml anhydrous pyridine (2 h at 80 °C) prior to analysis by 
gas chromatography mass spectrometry (GC/MS)53. IC50 determinations were performed using 50 μ M lanosterol 
as substrate to which azole antifungal agents were added in 2.5 μ l dimethylsulfoxide prior to incubation at 37 °C 
and addition of β -NADPHNa4. Determination of Kcat and Km values utilized CYP51 reconstitution assays that 
contained 0.13 μ M M. globosa CYP51 and 0.5 μ M AfCPR1 at sterol substrate concentrations of 6.25, 12.5, 25, 50, 
75 and 100 μ M with incubation at 37 °C for 5 min.
The CYP5218 fatty acid reconstitution assay system used was based on that previously described by 
Guengerich54 and contained 200 nM of CYP5218, 500 nM of cytochrome P450 reductase (A. fumigatus CPR152) 
or H. sapiens CPR55 or C. albicans CPR56, 50 μ M DLPC, 100 μ M fatty acid (lauric acid, myristic acid, palmitic 
acid, palmitoleic acid, oleic acid and linoleic acid), 4 mM glucose-6-phosphate, 3 U/ml yeast glucose-6-phosphate 
dehydrogenase in a final volume of 500 μ l with 0.1 M potassium phosphate (pH 7.4). Assay mixtures were incu-
bated at 37 °C for 5 min prior to initiation with 4 mM β -NADPHNa4 and then incubated for a further 60 min 
or overnight (~16 h) at 37 °C. Fatty acid metabolites were recovered by extraction with dichloromethane and 
dried in a vacuum centrifuge. Samples were derivatized with 200 μ l anhydrous pyridine and 250 μ l BSTFA:TMCS 
(99:1) (30 min at 80 °C) and extracted with 500 μ l of hexane, prior to analysis by GC/MS (Thermo GC Trace 
1300 and ISQ MS). GC analysis was performed with a 5% phenyl methylpolysiloxane column (DB5) (Agilent 
Technologies). The oven programme was as follows: initial: 70 °C, with 3 min hold; ramp: 10 °C min−1 to 180 °C 
(held for 2 min), 10 °C min−1 to 250 °C (held for 2 min) and 10 °C min−1 to 280 °C (held for 2 min). Data were 
analyzed using Thermo Xcalibur 2.2 software.
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M. globosa MIC100 determination. M. globosa ATCC MYA-4612 was grown for 7 days at 30 °C in modified 
Dixon medium (3.6% malt extract, 2% desiccated ox-bile, 1% Tween 40, 0.6% peptone, 0.2% glycerol, 0.2% oleic 
acid, pH adjusted to 6 with HCl) until a culture density of 1.5 × 105 cells ml−1 was obtained. Cells from 3 ml of 
stock culture were harvested, suspended in 1 ml of saline and used to inoculate 30 ml of fresh modified Dixon 
medium for use as M. globosa inoculums in MIC determinations. Stock azole concentrations of 1600, 800, 400, 
200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 μ g ml−1 were prepared in DMSO. These were diluted ten-fold with fresh 
modified Dixon media and 20 μ l of the diluted azole solutions were then mixed with 180 μ l of M. globosa inoc-
ulum in microtiter plate wells to yield final azole concentrations of 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125 
and 0 μ g ml−1. The microtiter plates were incubated at 30 °C for 7 days and then read. Each azole MIC100  determi-
nation was performed in triplicate.
Sterol analysis. M. globosa was grown in the absence and presence of azole antifungal for 7 days at 30 °C and 
non-saponifiable lipids extracted as previously reported57 and were derivatized with 0.1 ml BSTFA:TMCS (99:1) 
and 0.3 ml anhydrous pyridine (2 h at 80 °C) prior to analysis by GC/MS53. Individual sterols were identified by 
reference to relative retention times, mass ions and fragmentation patterns. Sterol composition was calculated 
using peak areas.
Chemicals. All fatty acids were obtained from Sigma-Aldrich (Poole, UK), Fluconazole, itraconazole and 
ketoconazole were obtained from Sigma-Aldrich (Poole, UK) whilst ketaminazole was supplied by professor 
T.R. Holman (University of California, Santa Cruz, CA). Lanosterol, eburicol and obtusifoliol were supplied by 
professor W. D. Nes (Texas Tech University, Lubbock, TX).
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